Olfr684, encoded by the Or56a4 gene, is an olfactory receptor in Mus musculus, part of the G-protein-coupled receptor (GPCR) superfamily. These receptors are critical for the sense of smell, detecting odorant molecules in the nasal epithelium and initiating neuronal responses that lead to olfactory perception. Olfactory receptors, including Olfr684, feature a 7-transmembrane domain structure, common to many neurotransmitter and hormone receptors, responsible for recognizing odorants and initiating G protein-mediated signal transduction. The activation of these receptors by specific odorants leads to various intracellular events, typically involving the modulation of second messengers such as cyclic AMP (cAMP). The complexity of GPCR signaling, including that of olfactory receptors like Olfr684, makes the identification of direct inhibitors challenging. Therefore, potential indirect inhibitors are considered, focusing on modulating related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists, such as propranolol, atenolol, and metoprolol, reduce cellular cAMP levels, a crucial component in GPCR signaling. This reduction in cAMP may indirectly affect the signaling pathways of GPCRs, potentially influencing the function of olfactory receptors like Olfr684. Calcium channel blockers, including nifedipine and verapamil, alter intracellular calcium levels, another vital factor in GPCR signaling. Changes in calcium dynamics can indirectly affect the function of GPCRs, including olfactory receptors.
Additionally, targeting other GPCR pathways, such as those modulated by angiotensin II receptors, offers another indirect approach to modulate olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting receptors like Olfr684. Alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine might also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In summary, the indirect inhibition of Olfr684 involves understanding GPCR biology and the interconnected nature of cellular signaling pathways. The listed chemicals provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr684. While direct inhibition presents significant challenges, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, reduces cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr684. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, potentially indirectly influencing GPCR signaling pathways and impacting Olfr684 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr684. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr684. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr684. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr684. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr684. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr684. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr684. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr684. | ||||||